

DECLARATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Kai KROHN

Group: 1634

Serial No: 09/508,658

Examiner: SITTON, Jehanne

Souaya

Filed: November 3, 2000

For: NOVEL GENE DEFECTIVE IN APECED AND ITS USE

Attorney docket: U012653-9

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I, **Pärt Peterson**, a citizen of **Estonia** declare that:

Graduated from the University of Tartu, Estonia, and obtained the PhD degree from the University of Tampere, Finland. Currently Professor of Molecular Pathology, Faculty of Medicine, University of Tartu, Estonia

That I have read and understood the specification of US patent application 09/508,658.

At the time that the priority application FI 973762 was being prepared for filing, a typographical error was made. The error that was made appears in the published specification of the PCT application (publication number WO99/15559) at page 5, line 24 and page 8, lines 26-27. The error is that the mutation is incorrectly positioned at amino acid 42 and is also incorrectly identified as the mutation K42E. The mutation is in fact at amino acid position 83 and it is mutation K83E (83 for the amino acid at position 83).


The inventors noted the mistake in the description only when they were submitting the manuscript for the article "Positional cloning of the APECED gene", Nature Genetics, 1997 Dec; 17(4):393-8). A copy of the article is attached. The article was published after the filing of Finnish patent application FI 973762.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to



be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statement may jeopardize the validity of the application or any patent issued thereon.

Signed this 22 day of May 2006

A handwritten signature in black ink, consisting of stylized initials followed by a long horizontal stroke.

---

Signature

DECLARATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re application of : Kai KROHN

Group: 1634

Serial No: 09/508,658

Souaya

Filed: November 3, 2000



Examiner: SITTON, Jehanne

For: NOVEL GENE DEFECTIVE IN APECED AND ITS USE

Attorney docket: U012653-9

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I, Maarit Lahti (nee Heino) a citizen of Finland declare that:

Education: MD, PhD. Currently working as resident in the department of anesthesia and intensive care.

That I have read and understood the specification of US patent application 09/508,658.

At the time that the priority application FI 973762 was being prepared for filing, a typographical error was made. The error that was made appears in the published specification of the PCT application (publication number WO99/15559) at page 5, line 24 and page 8, lines 26-27. The error is that the mutation is incorrectly positioned at amino acid 42 and is also incorrectly identified as the mutation K42E. The mutation is in fact at amino acid position 83 and it is mutation K83E (83 for the amino acid at position 83).

The inventors noted the mistake in the description only when they were submitting the manuscript for the article "Positional cloning of the APECED gene", Nature Genetics, 1997 Dec; 17(4):393-8). A copy of the article is attached. The article was published after the filing of Finnish patent application FI 973762.


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that

willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statement may jeopardize the validity of the application or any patent issued thereon.

Signed this 1<sup>st</sup> day of June 2006

---

Signature

A handwritten signature in black ink, consisting of a series of connected loops and a long horizontal stroke at the end.

DECLARATION


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Kai KROHN

Group: 1634

Serial No: 09/508,658

Filed: November 3, 2000



Examiner: SITTON, Jehanne Souaya

For: NOVEL GENE DEFECTIVE IN APECED AND ITS USE

Attorney docket: U012653-9

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I, Kai Krohn, a citizen of Finland. declare that:

I have graduated from the Helsinki University, Finland with an MD (1963) and PhD (1968) degrees, have served as professor of Pathology and also as Professor of Biotechnology at the Tampere University, Finland and have more than 40 years experience in the study of autoimmunity.

I am currently the CRO and COB for Dermagene Inc, Helsinki, Finland.

That I have read and understood the specification of US patent application 09/508,658.

At the time that the priority application FI 973762 was being prepared for filing, a typographical error was made. The error that was made appears in the published specification of the PCT application (publication number WO99/15559) at page 5, line 24 and page 8, lines 26-27. The error is that the mutation is incorrectly positioned at amino acid 42 and is also incorrectly identified as the mutation K42E. The mutation is in fact at amino acid position 83 and it is mutation K83E (83 for the amino acid at position 83).

The inventors noted the mistake in the description only when they were submitting the manuscript for the article "Positional cloning of the APECED gene", Nature Genetics, 1997 Dec; 17(4):393-8). A copy of the article is attached. The article was published after the filing of Finnish patent application FI 973762.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statement may jeopardize the validity of the application or any patent issued thereon.

Signed this 21th day of May, 2006

A handwritten signature in black ink, consisting of several overlapping loops and a long horizontal stroke, positioned above a solid horizontal line.

Signature

## DECLARATION

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Kai KROHN

Group: 1634

Serial No: 09/508,658

Examiner: SITTON, Jehanne Souaya

Filed: November 3, 2000

For: NOVEL GENE DEFECTIVE IN APECED AND ITS USE

Attorney docket: U012653-9

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

, Hamish Steele Scott, a citizen of Australia declare that:

#### **Academic Qualifications**

1983-1985 BSc, Genetics and Biochemistry, University of Adelaide  
1986 BSc Honours, Department of Genetics, University of Adelaide  
1989-1992 PhD (part time), Department of Chemical Pathology, Women's and Children's Hospital (formerly the Adelaide Children's Hospital), and Department of Pathology, School of Medicine, University of Adelaide

#### **Past positions**

1987 Research assistant in the Microbiology Department, The School of Biological Sciences, The Flinders University of South Australia.  
1988-92 Research assistant, Lysosomal Diseases Research Unit, Department of Chemical Pathology, Women's and Children's Hospital.  
1992-95 Raymond A. Bryan IV Postdoctoral Fellow, Research officer, Lysosomal Diseases Research Unit, Department of Chemical Pathology, Women's and Children's Hospital.  
1995-97 CJ Martin Postdoctoral Fellow, NHMRC in Division of Medical Genetics, University of Geneva Medical School, Switzerland.  
1997-2000 Lecturer and faculty member ("Maître Assistant") in the Division of Medical Genetics, University of Geneva Medical School, Switzerland.  
1998-2000 Deputy Laboratory Director, Division of Medical Genetics, University of Geneva Medical School, Switzerland.

#### **Current positions**

2000- present Laboratory Head, Genetics and Bioinformatics Division (now Division of

Molecular Medicine), WEHI

2001- present NHMRC Senior Research Fellow, Genetics and Bioinformatics Division (now Division of Molecular Medicine), WEHI

That I have read and understood the specification of US patent application 09/508,658.

At the time that the priority application FI 973762 was being prepared for filing, a typographical error was made. The error that was made appears in the published specification of the PCT application (publication number WO99/15559) at page 5, line 24 and page 8, lines 26-27. The error is that the mutation is incorrectly positioned at amino acid 42 and is also incorrectly identified as the mutation K42E. The mutation is in fact at amino acid position 83 and it is mutation K83E (83 for the amino acid at position 83).


The inventors noted the mistake in the description only when they were submitting the manuscript for the article "Positional cloning of the APECED gene", Nature Genetics, 1997 Dec; 17(4):393-8). A copy of the article is attached. The article was published after the filing of Finnish patent application FI 973762.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statement may jeopardize the validity of the application or any patent issued thereon.

Signed this 23<sup>rd</sup> day of May 2006

---

Signature

The image shows a handwritten signature in black ink. The signature appears to be 'Haimant Scott'. The first name 'Haimant' is written in a cursive style, and the last name 'Scott' is written in a more stylized, blocky cursive. The signature is positioned below a horizontal line.



## DECLARATION

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Kai KROHN

Group: 1634

Serial No: 09/508,658

Examiner: SITTON, Jehanne Souaya

Filed: November 3, 2000

For: NOVEL GENE DEFECTIVE IN APECED AND ITS USE

Attorney docket: U012653-9

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I, Maria Lalioti, a citizen of Greece, declare that:

B.Sc. in Biology; University of Athens, Greece; 1991  
M.Sc. Reproductive Biology; University of Geneva, Switzerland; 1993  
M.Sc. Medical Biology; University of Geneva, Switzerland; 1994  
Ph.D. Human Genetics; University of Geneva, Switzerland; 1998  
Postdoc Biochemistry; University of Birmingham, UK; 2001  
Postdoc Human Genetics; Yale University School of Medicine; USA; 2005

Current position: Assistant Professor, Yale University School of Medicine,  
Department of Obstetrics, Gynecology and Reproductive Sciences.

That I have read and understood the specification of US patent application  
09/508,658.

At the time that the priority application FI 973762 was being prepared for filing, a typographical error was made. The error that was made appears in the published specification of the PCT application (publication number WO99/15559) at page 5, line 24 and page 8, lines 26-27. The error is that the mutation is incorrectly positioned at amino acid 42 and is also incorrectly identified as the mutation K42E. The mutation is in fact at amino acid position 83 and it is mutation K83E (83 for the amino acid at position 83).

The inventors noted the mistake in the description only when they were submitting the manuscript for the article "Positional cloning of the APECED gene",

Nature Genetics, 1997 Dec; 17(4):393-8). A copy of the article is attached. The article was published after the filing of Finnish patent application FI 973762.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statement may jeopardize the validity of the application or any patent issued thereon.

Signed this 30 day of May 2006

---

Signature

A handwritten signature in black ink, appearing to read 'Maria Lalioti', written over a horizontal line.

Maria Lalioti

DECLARATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re application of: Kai KRON

Group: 1634

Serial No: 09/508,658

Souaya

Filed: November 3, 2000



Examiner: SITTON, Jehanne

For: NOVEL GENE DEFECTIVE IN APECED AND ITS USE

Attorney docket: U012653-9

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I, Nobuyoshi Shimizu a citizen of Japan declare that:

I was educated in Japan, received PhD degree in Molecular Biology from Nagoya University (1970), employed as postdoctoral research fellow at University of California San Diego and Yale University (1971-1977), engaged in University of Arizona as Professor (1977-1983) and currently Professor and Chairman of Department of Molecular Biology, Keio University School of Medicine, Japan.


That I have read and understood the specification of US patent application 09/508,658.

At the time that the priority application FI 973762 was being prepared for filing, a typographical error was made. The error that was made appears in the published specification of the PCT application (publication number WO99/15559) at page 5, line 24 and page 8, lines 26-27. The error is that the mutation is incorrectly positioned at amino acid 42 and is also incorrectly identified as the mutation K42E. The mutation is in fact at amino acid position 83 and it is mutation K83E (83 for the amino acid at position 83).

The inventors noted the mistake in the description only when they were submitting the manuscript for the article "Positional cloning of the APECED gene", Nature Genetics, 1997 Dec; 17(4):393-8). A copy of the article is attached. The article was published after the filing of Finnish patent application FI 973762.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statement may jeopardize the validity of the application or any patent issued thereon.

Signed this 25<sup>th</sup> day of May 2006

A handwritten signature in cursive script, appearing to read "Nobuyoshi Shimizu", written in black ink.

---

Signature

# DECLARATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kai KROHN

Group: 1634

Serial No: 09/508,658

Examiner: SITTON, Jehanne Souaya

Filed: November 3, 2000

For: NOVEL GENE DEFECTIVE IN APECED AND ITS USE

Attorney docket: U012653-9

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I, Jun KUDOH, a citizen of Japan declare that:

Education:

1979 – 1984: Graduate School of Science, Osaka University, Ph. D.

Employment:

1985 – 2003: Research Associate – Assistant Professor, Department of Molecular Biology, Keio University School of Medicine

2003 – present: Associate Professor, Department of Molecular Biology, Keio University School of Medicine.

That I have read and understood the specification of US patent application 09/508,658.

At the time that the priority application FI 973762 was being prepared for filing, a typographical error was made. The error that was made appears in the published specification of the PCT application (publication number WO99/15559) at page 5, line 24 and page 8, lines 26-27. The error is that the mutation is incorrectly positioned at amino acid 42 and is also incorrectly identified as the mutation K42E. The mutation is in fact at amino acid position 83 and it is mutation K83E (83 for the amino acid at position 83).


The inventors noted the mistake in the description only when they were submitting the manuscript for the article "Positional cloning of the APECED gene", Nature Genetics, 1997 Dec; 17(4):393-8). A copy of the article is attached. The article was published after the filing of Finnish patent application FI 973762.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statement may jeopardize the validity of the application or any patent issued thereon.

Signed this 25<sup>th</sup> day of May, 2006

---

Signature

A handwritten signature in black ink, appearing to read "Gur Kundra", written in a cursive style.